- Home
- ATAI vs SENS Comparison
ATAI vs SENS Comparison
Compare ATAI & SENS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATAI
- SENS
- Stock Information
- Founded
- ATAI 2018
- SENS 1996
- Country
- ATAI Germany
- SENS United States
- Employees
- ATAI N/A
- SENS N/A
- Industry
- ATAI Biotechnology: Pharmaceutical Preparations
- SENS Industrial Machinery/Components
- Sector
- ATAI Health Care
- SENS Industrials
- Exchange
- ATAI Nasdaq
- SENS Nasdaq
- Market Cap
- ATAI 444.7M
- SENS 472.9M
- IPO Year
- ATAI 2021
- SENS N/A
- Fundamental
- Price
- ATAI $3.48
- SENS $0.50
- Analyst Decision
- ATAI Strong Buy
- SENS Strong Buy
- Analyst Count
- ATAI 3
- SENS 4
- Target Price
- ATAI $11.67
- SENS $1.66
- AVG Volume (30 Days)
- ATAI 8.9M
- SENS 7.2M
- Earning Date
- ATAI 08-12-2025
- SENS 08-06-2025
- Dividend Yield
- ATAI N/A
- SENS N/A
- EPS Growth
- ATAI N/A
- SENS N/A
- EPS
- ATAI N/A
- SENS N/A
- Revenue
- ATAI $1,863,000.00
- SENS $23,682,000.00
- Revenue This Year
- ATAI $423.05
- SENS $60.14
- Revenue Next Year
- ATAI N/A
- SENS $36.55
- P/E Ratio
- ATAI N/A
- SENS N/A
- Revenue Growth
- ATAI 572.56
- SENS 1.64
- 52 Week Low
- ATAI $1.03
- SENS $0.25
- 52 Week High
- ATAI $4.00
- SENS $1.40
- Technical
- Relative Strength Index (RSI)
- ATAI 60.69
- SENS 40.41
- Support Level
- ATAI $3.06
- SENS $0.57
- Resistance Level
- ATAI $3.70
- SENS $0.61
- Average True Range (ATR)
- ATAI 0.27
- SENS 0.03
- MACD
- ATAI 0.00
- SENS -0.00
- Stochastic Oscillator
- ATAI 52.46
- SENS 10.63
About ATAI ATAI Life Sciences N.V.
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company on a mission to develop effective mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 (buccal film DMT) for treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder. It is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for TRD.
About SENS Senseonics Holdings Inc.
Senseonics Holdings Inc is a medical technology company. It is focused on the design, development, and commercialization of glucose monitoring system, which helps people to manage their diabetes community with differentiated, long-term implantable glucose management technology. Its products and services include a Continuous glucose monitoring system, Sensor, Smart transmitter, and Mobile app. The firm has a Glucose monitoring product segment. The majority of the revenue is generated outside of the United States.